Glaucoma surgery that when combined with cataract surgery, the IOP is reduced even further than when done alone. Long term (three year) results have been published both in the US and Europe demonstrating a significant and sustained reduction in both eye pressure and the number of glaucoma medications required for glaucoma control. Certain cells within the eye's ciliary body produce aqueous humor. A ciliary destructive or cyclodestructive procedure is one that aims to destroy those cells in order to reduce intraocular pressure. Cyclocryotherapy, or cyclocryopexy, uses a freezing probe. Cyclophotocoagulation, also known as transscleral cyclophotocoagulation, ciliary body ablation, cyclophotoablation, and cyclophototherapy, uses
Minimally invasive glaucoma surgery to augment outflow to the suprachoroidal space in order to control intraocular pressure; it is indicated for the treatment of primary open-angle glaucoma. The stent is implanted through an ab interno approach and inserted into the supraciliary space (between the ciliary body and sclera), effectively creating a controlled cyclodialysis cleft, which is kept open by the device. The first clinical data on the device was presented in 2010 showed sustained IOP lowering and MIGS-like safety profile. This has been substantiated in subsequent studies in the combined setting with cataract surgery and as a stand-alone treatment for patients failing glaucoma topical